In recent years, new α-particle–, β⁻-particle–, and Auger electron–emitting radiometals—such as ⁶⁷Cu, ⁴⁷Sc, ¹⁶⁶Ho, ¹⁶¹Tb, ¹⁴⁹Tb, ²¹²Pb/²¹²Bi, ²²⁵Ac, and ²¹³Bi—have been produced and evaluated (pre)clinically for therapeutic purposes. In this short review article, the most important routes of production of these radiometals are critically discussed, as are examples of their application in preclinical and clinical studies.
No takes yet. Share an insight, caveat, or question.
Müller et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: